Mucormycosis diagnosed during induction chemotherapy in five pediatric patients with acute lymphoblastic leukemia

Mucormycosis in pediatric oncology patients is a rare invasive fungal infection associated with significant morbidity and mortality. We describe five patients diagnosed with mucormycosis during induction chemotherapy for acute lymphoblastic leukemia at our institution. All of the patients in our series survived, some in spite of having disseminated disease. Most of the patients’ chemotherapy was modified with the aim of controlling their leukemia while minimizing immunosuppression until their fungal infection was under control. Although mucormycosis is frequently fatal, rapid diagnosis and a multidisciplinary approach can lead to excellent outcomes, even in patients undergoing intensive chemotherapy.

[1]  N. Santoro,et al.  Invasive mucormycosis in children with cancer: A retrospective study from the Infection Working Group of Italian Pediatric Hematology Oncology Association , 2018, Mycoses.

[2]  D. Kuo,et al.  Severe Neuropathic Pain With Concomitant Administration of Vincristine and Posaconazole. , 2018, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[3]  M. Arendrup,et al.  Isavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature , 2018, Mycopathologia.

[4]  M. Ertem,et al.  Toxicity of Vincristine Combined With Posaconazole in Children With Acute Lymphoblastic Leukemia , 2017, Journal of pediatric hematology/oncology.

[5]  J. Duchin,et al.  Seasonal clustering of sinopulmonary mucormycosis in patients with hematologic malignancies at a large comprehensive cancer center , 2017, Antimicrobial Resistance & Infection Control.

[6]  P. Escribano,et al.  Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates , 2017, PloS one.

[7]  D. Seidel,et al.  Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries , 2016, BMC Infectious Diseases.

[8]  A. Borkhardt,et al.  Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Kontoyiannis,et al.  Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  G. Lenz,et al.  Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemia , 2016, Annals of Hematology.

[11]  A. Velegraki,et al.  A Prospective, International Cohort Study of Invasive Mold Infections in Children. , 2015, Journal of the Pediatric Infectious Diseases Society.

[12]  S. Balajee,et al.  Mucormycosis Outbreak Associated With Hospital Linens , 2014, The Pediatric infectious disease journal.

[13]  Sandeep Jain,et al.  Successful outcome of mucormycosis in two children on induction therapy for acute lymphoblastic leukemia , 2013, Indian Journal of Medical and Paediatric Oncology.

[14]  B. Moriyama,et al.  Adverse interactions between antifungal azoles and vincristine: review and analysis of cases , 2012, Mycoses.

[15]  D. Kontoyiannis,et al.  How I treat mucormycosis. , 2011, Blood.

[16]  S. Kabra,et al.  ‘Primary cutaneous mucormycosis during induction chemotherapy in a child with acute lymphoblastic leukemia’ , 2009, Indian journal of pediatrics.

[17]  J. Desenclos,et al.  Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006 , 2009, Emerging infectious diseases.

[18]  Russell E. Lewis,et al.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.

[19]  J. Englund,et al.  Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.